Overview

RBT-1 Phase 1b Clinical Trial in Healthy Volunteers and Subjects With CKD

Status:
Withdrawn
Trial end date:
2019-03-31
Target enrollment:
Participant gender:
Summary
A Phase 1b study to evaluate the safety, tolerability and pharmacodynamic effect of RBT-1 in healthy volunteers and subjects with stage 3b-4 CKD.
Phase:
Phase 1
Details
Lead Sponsor:
Renibus Therapeutics, Inc.
Renibus Therapuetics, Inc.
Treatments:
Ferric Compounds
Ferric Oxide, Saccharated
Iron
Protoporphyrin IX
Tin protoporphyrin IX